The factor H-related protein family (CFHR) is a group of minor plasma proteins genetically and structurally related to complement factor H (fH). Notably, deficiency of CFHR1/CFHR3 associates with protection against age-related macular degeneration, and with the presence of anti-fH autoantibodies in atypical Hemolytic Uremic Syndrome (aHUS). We have developed a proteomics strategy to analyze the CFHR proteins in plasma samples from controls, aHUS patients and type II Membranoproliferative Glomerulonephritis (MPGN2/DDD) patients. Here, we report on the identification of individuals carrying novel deficiencies of CFHR1, CFHR3 and CFHR1/CFHR4A, resulting from point mutations in CFHR1 and CFHR3 or from a rearrangement involving CFHR1 and CFHR4. Remarkably, aHUS patients lacking CFHR1 -but not those lacking CFHR3-present anti-fH autoantibodies, suggesting that generation of these antibodies is specifically related to the CFHR1 deficiency. We also report the characterization of a novel CFHR1 polymorphism, resulting from a gene conversion event between CFH and CFHR1, which strongly associates with aHUS. The risk allotype CFHR1*B, with greater sequence similarity to fH, may compete with fH, decreasing protection of cellular surfaces against complement damage. In summary, our comprehensive analyses of the CFHR proteins have improved our understanding of these proteins and provided further insights into aHUS pathogenesis.
INTRODUCTION
The Complement system is a major component of the innate immune response to infection, and it is also involved in immunecomplex removal and the destruction of damaged or anomalous autologous cells. Improper complement activation is prevented by several plasma and membranes proteins, which perform a regulatory, inhibitory function. Complement factor H (fH) is the main inhibitor of the alternative pathway of the Complement system 1 consisting of SCRs 1 to 7 plus an additional hydrophobic tail of four amino acids 5, 6 . In close proximity to CFH there are 5 genes coding for proteins showing sequence and structural homology to fH that are known as fH-related proteins (CFHRs) 7 . CFH and the five CFHR genes (CFHR1-5) lie in a head-to-tail arrangement and are thought to have originated by successive duplication events within the RCA gene cluster 8 .
The CFHR proteins were first identified by Western-blot analysis of human plasma with polyclonal anti-fH antibodies 9 . They are all composed of SCR domains showing different degrees of identity with the homologous domains in fH. The concentrations of CFHR proteins in plasma are much lower than that of fH, and their biological function is currently unknown. Binding to the physiological fH ligand C3b has been reported for CFHR1, CFHR3, CFHR4 and CFHR5 [10] [11] [12] , and C3 convertase regulatory activity has been detected in CFHR5 13 . Most recently, CFHR1 has been shown to inhibit the C5 convertase and the membrane attack complex (MAC) formation 14 , suggesting a sequential and complementary role for fH and CFHR1 in complement regulation.
The CFH-CFHR1-5 genomic region includes a number of large genomic duplications involving different exons of the CFH and CFHR1-5 genes, which have mediated genomic rearrangements through mechanisms of gene conversion and non-
homologous recombination. Several examples of gene conversion events between exon
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Similarly, there is robust evidence of major rearrangements in the CFH-CFHR1-5 gene region that result in the deletion of the CFHR1 and CFHR3 genes (Δ CFHR1-CFHR3 ) 16, 17 and, occasionally, in the generation of CFH::CFHR1 hybrid genes 18 . These CFH-CFHR1-5 rearrangements can be easily identified by MLPA (Multiplex Ligationdependent Probe Amplification) technologies 18 or by Western-blot in the case of homozygote carriers 17 . Chromosomes carrying both the deletion of the CFHR1 and CFHR3 genes and a CFH::CFHR1 hybrid gene are rare and are specifically associated with aHUS 18 . In contrast, the deletion of the CFHR1 and CFHR3 genes (Δ CFHR1-CFHR3 ) without rearrangements in CFH is a common genetic polymorphism that is associated with lower risk of AMD 16, 19 and with increased risk of aHUS due to the generation of anti-fH autoantibodies 17, 20, 21 . The rearrangement that results in Δ CFHR1-CFHR3 is not a recurring phenomenon but a single event that became fixed in the human population a long time ago 19 . Additional genetic alterations within the CFH-CFHR1-5 region are expected, and they are likely to have pathological implications. In this context, the characterization of the products of CFH and CFHR1-CFHR5 genes would be most helpful.
We have characterized the CFHR proteins present in plasma samples from control individuals, aHUS patients and MPGN2/DDD patients by Western-blot, and developed a strategy based on the analysis of partially purified CFHR proteins by twodimensional gel electrophoresis that increases resolution of these proteins and reveals novel structural features. Our results improve our understanding of the genetic variability at the CFHR region. They suggest a specific relationship between the deficiency of CFHR1 and the generation of anti-fH autoantibodies and reveal a novel polymorphism in CFHR1 that confers increased risk to aHUS, thus providing further insights into the pathogenesis of aHUS.
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MATERIALS AND METHODS

Samples from Patient and Control Individuals
Blood samples were drawn from 151 patients with a clinical diagnosis of aHUS and from 13 MPGN2/DDD patients. Serum and EDTA-plasma aliquots were stored immediately at -80ºC until used. Peripheral-blood leukocytes were used to prepare genomic DNA. All samples were obtained in the context of research studies on HUS and MPGN2/DDD that have the approval of the Ethics Committee from University Hospital La Paz. Written informed consent was obtained from patients or their relatives in accordance with the Declaration of Helsinki. A previously described cohort of 141 AMD patients 22 was also included in some genetic studies as a disease control group.
Blood samples were also drawn from a total of 105 control individuals (59 female and 46 male). 68 controls were normal healthy adult volunteers (aged 21-73, median 34 y); 37 controls were anonymous children (aged 2-16, median 6 y) that were about to undergo post-traumatic surgery in University Hospital La Paz but did not present signs of any infectious-related condition. Serum, EDTA-plasma and DNA were obtained from these control samples, which were used for Western-blot and genetic analysis.
DNA samples from other 125 control individuals 22 were also available for some genetic studies.
Detection of fH autoantibodies in serum samples
Factor H autoantibodies in serum samples were detected with an ELISA assay following the previously described by Dragon-Durey et al. 23 
Heparin-Sepharose chromatography
Factor H, CFHL1, and CFHR proteins were partially purified by affinity chromatography on heparin-Sepharose (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Serum samples were dialyzed at 4ºC against 20 mM Tris-HCl pH 7.5, containing 50 mM NaCl (equilibrating buffer). Dialyzed sera were incubated overnight at 4ºC with heparin-Sepharose beads. Beads were then centrifuged and the supernatant stored for further analysis. After several washes in equilibrating buffer, bound proteins were eluted with 20 mM Tris-HCl pH 7.5, 500 mM NaCl.
Two-dimensional electrophoresis (2-DE)
Isoelectrofocusing (IEF) was used in the first dimension and standard SDS-PAGE in the second dimension. For IEF, Immobilized pH Gradient strips (IPG strips) of 7 cm and different pH linear range were used (pH 3-10 or pH 4-7 ImmobilineDrystrips, GE Healthcare; pH 5-8 ReadyStrips, Bio-Rad Laboratories, Inc., Hercules, CA, USA). Samples were resuspended in IEF buffer (0.5 % IPG buffer, 8M urea, 2% Chaps, 0.002% bromofenol blue) and loaded onto the IPG strips manually. IPG strips were rehydrated at 20ºC for 15 hours at 50 V, 1 hour at 100 V and 1 hour at 1000 V in an IPGphor I horizontal apparatus (GE Healthcare). Isoelectrofocusing was carried out at 5000 V for 5h30min. IPG strips were equilibrated in 50 mM Tris-HCl, pH 6.8 buffer, containing 6M urea, 87% glycerol, 2% SDS, 0.002% bromofenol blue. For the second dimension, equilibrated IPG strips were placed on top of a 5% stacking-10% resolving polyacrylamide minigel, and electrophoresed in the following conditions: 50 mA/30 min + 75 mA/30 min + 100 mA/ 90 min.
After electrophoresis, gels were either stained with Coomassie Brilliant Blue G-250 (USB Corporation, Cleveland, OH, USA) for Mass Spectrometry (Proteomics Unit, Universidad Complutense, Madrid, Spain), or processed for Western-blot analysis.
Western-blot analysis
Proteins were transferred to nitrocellulose membranes at 100 V for 1 hour in a Mini Trans-Blot Cell apparatus (Bio-Rad). Membranes were blocked in ECL Advance blocking agent (GE Healthcare) and incubated with primary antibodies for 2 hours.
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Description of primary antibodies
Polyclonal antibodies were raised in rabbits. Antibody αCFHR1 was generated in the laboratory, and recognizes fH, CFHL1, and the two isoforms of CFHR1:
CFHR1α (37 kDa) and CFHR1β (43 kDa), containing one and two carbohydrate molecules, respectively 25 . Antibody αCFHR3/4 was provided by Prof. Peter Zipfel (Hans-Knöll Institute, Jena, Germany). This antibody recognizes fH, CFHL1, CFHR3 and the two products of the CFHR4 gene 26 : CFHR4A (86 kDa) and CFHR4B (46 kDa). 
Genetic studies
Rearrangements in the CFH-CFHR1-5 genomic region were analyzed by MLPA (Multiplex Ligation-Dependent Probe Amplification). Copy number variations of CFHR1 and CFHR3 were determined using the P236 A1 ARMD mix 1 from MRC-Holland (Amsterdam, The Netherlands). Since this mix does not include probes for the CFHR4 gene, another MLPA reaction was designed with probes for specific exons of CFH and the 5 CFHR genes. These probes were synthesized by Sigma-Aldrich and also included control probes for the BCAP31 gene, located on chromosome X, and for the MORF4L1 gene, located on chromosome 15. The hybridization sequences are shown in Table I . Each probe pair hybridized to sequences immediately adjacent to the target region; the 3' probes (R) were 5'-phosphorylated to provide a free phosphate for the ligation reaction. A non-specific sequence between the hybridizing nucleotides and the nucleotides recognizing the primers was introduced to adjust the length of the fragments. The reagents for the MLPA reactions were purchased from MRC-Holland (Amsterdam, The Netherlands), and the reaction was carried out following the manufacturer's protocol. 2 µl of the final product plus 0.2 µl of internal standard All CFHR1 and CFHR3 exons were amplified by PCR using specific oligonucleotides (Table II) . Direct sequencing of the PCR products was performed using the BigDye Terminator V1.1 sequencing kit (Applied Biosystems) on an ABI Prism 3100-Avant Genetic Analyzer.
RESULTS
Identification of CFHR proteins deficiencies by Western-blot
Serum samples from 115 control individuals, 149 aHUS patients and 13 MPGN2/DDD patients were analyzed by SDS-PAGE and Western-blot with 3 polyclonal antibodies that recognize fH, its alternative splicing product, CFHL1, and the CFHR1-5 proteins. As illustrated in figure 1, four banding patterns revealing different CFHR proteins deficiencies were observed: deficiency of both CFHR1 and CFHR3 (DefR1R3), isolated deficiency of CFHR1 (DefR1), isolated deficiency of CFHR3 (DefR3), and deficiency of both CFHR1 and CFHR4A (DefR1R4A). Figure 1 also illustrates the normal, most common situation, where all CFHR proteins are present.
The frequency of these complete CFHR deficiencies in control individuals, aHUS and MPGN2/DDD patients is shown in Table III . In agreement with previous reports, 17, 20, 21 we found that DefR1R3, present in approximately 2% of normal controls, is associated with increased risk of aHUS (12/149 vs 2/115; P= 0.026; OR= 4.95; 95% CI, 1.1-22.6), and is particularly elevated among patients with autoantibodies against fH (3 out of 7 patients; see below). Isolated deficiency of CFHR1 (DefR1) or CFHR3 (DefR3), as well as combined CFHR1/CFHR4A deficiency (DefR1R4A), were only found among aHUS and MPGN2/DDD patients.
Genetic analysis of CFHR deficiencies
Deficiency of CFHR1/CFHR3
Genetic studies using specific MLPA probes showed that all individuals presenting the DefR1R3 pattern were homozygous for the 84 kb-long genomic deletion (Δ CFHR1-CFHR3 ) previously described by Zipfel et al. 17 . Analysis of this deletion was also carried out in additional control samples, as well as in a previously described cohort of AMD patients 22 . The results are shown in Table IV . In agreement with previous observations, 16, 19 we found that the Δ CFHR1-CFHR3 deletion is a protective factor for AMD. However, the Δ CFHR1-CFHR3 allele frequencies show no differences between controls, aHUS or MPGN2/DDD; nonetheless, there is an excess of Δ CFHR1-CFHR3 homozygotes in the aHUS cohort that significantly deviates from the expected value estimated from the Δ CFHR1-CFHR3 allele frequency. Thus, the aHUS population is not in Hardy-Weinberg equilibrium for the Δ CFHR1-CFHR3 polymorphism most likely because of the presence of patients with fH autoantibodies, as discussed below.
Novel CFHR deficiencies
Analysis of the Δ CFHR1-CFHR3 deletion was also carried out in the 6 patients presenting the novel CFHR deficiency patterns (DefR1, DefR3 and DefR1R4A).
Additional MLPA analyses within the CFHR1-5 subregion of the RCA gene cluster, and direct sequencing of CFHR1 and CFHR3 genes, were also performed in these patients (see Materials and Methods for details). These studies identified novel genetic alterations associated with the CFHR deficiencies that are summarized in Table V . The 5 patients presenting CFHR1 or CFHR3 deficiency carry Δ CFHR1-CFHR3 in heterozygosis and therefore lack one CFHR1 and one CFHR3 allele. Sequencing analyses of the CFHR1 gene revealed a heterozygous mutation in patient H119 that resulted in the substitution of a serine for a stop codon at position 160 in the SCR3 domain (c.479C>A; Ser160Stop) ( Figure 2A ). This is a null mutation that generates a truncated CFHR1 protein that is likely not expressed. Similarly, sequencing analyses of all the exons and the promoter region of the CFHR3 gene identified a heterozygous mutation in patient H123 that results in the deletion of two nucleotides in exon 6 (c.839_840delTA). This deletion causes a frameshift mutation (p.I280KfsX6) that generates a stop codon 6 amino acids downstream position 280, at the beginning of the SCR5 domain ( Figure   2B ). Mutation c.839_840delTA is therefore a null mutation that generates a truncated CFHR3 protein most likely not expressed. No mutations in CFHR3 were found in patients H150 and GN11.
MLPA analysis in patients H177 (DefR1R4A) and GN9 (DefR1) resulted in the identification of a novel rearrangement that specifically removes the CFHR1 and CFHR4 genes ( Figure 3A ). We refer to this deletion as Δ CFHR1-CFHR4 , and it probably involves a non-homologous recombination event in the 3'regions of the CFHR3 and CFHR4 genes. Patient H177, lacking both CFHR1 and CFHR4, is homozygous for this rearrangement, while patient GN9, lacking only CFHR1, is a compound heterozygote for Δ CFHR1-CFHR4 and Δ CFHR1-CFHR3 ( figure 3B ). Further analysis of all the individuals in our aHUS, MPGN2/DDD and control cohorts identified the presence of this heterozygous rearrangement in some additional individuals ( Figure 3C ), illustrating that Δ CFHR1-CFHR4 is a polymorphic trait in humans, although probably less frequent than
CFHR protein deficiencies in aHUS patients with anti-fH autoantibodies
Serum samples from control individuals, aHUS and MPGNII/DDD patients were screened for the presence of anti-fH autoantibodies basically as described 23 .
Autoantibodies were only detected in 7 pediatric aHUS patients. The autoantibody titer and the main complement findings in the first serum sample available from these patients are shown in Table VI . Additional data on plasma treatment and renal function are also included in this table. Characterization of CFHR proteins by Western-blot revealed distinct CFHR deficiencies in 5 of these 7 patients (Table VII) . Combined deficiency of both CFHR1 and CFHR3 was observed in only 3 patients (H87, H108, and H154), who were homozygous for the Δ CFHR1-CFHR3 deletion. Deficiency of CFHR1 and CFHR4A was observed in one patient (H177), presenting homozygous Δ CFHR1-CFHR4 deletion. Finally, a single deficiency of CFHR1 was detected in another patient (H119) who was a compound heterozygote for the Δ CFHR1-CFHR3 deletion and a missense mutation in the CFHR1 gene. Therefore, 5 out of the 7 patients with fH autoantibodies showed homozygous CFHR1 deficiency, but the underlying genetic defects differ between the patients. Importantly, none of the patients presented mutations in the CFH, CFI, CFB, C3 or MCP genes.
Two-dimensional (2D) analysis of CFHR proteins.
The analysis of serum samples by monodimensional electrophoresis and
Western-blot allowed detection of all products of CFH and CFHR genes thus far described. However, the bands corresponding to CFHR3 and CFHR4B overlap and could not be properly resolved. A similar situation was observed with CFHR1β and CFHL1. To solve these difficulties and properly characterize these proteins, we performed two-dimensional electrophoresis, using isoelectrofocusing in the first dimension (IEF) and SDS-PAGE in the second dimension.
Affinity chromatography on heparin-Sepharose at low ionic strength (50 mM NaCl) was used to remove major serum components (albumin and immunoglobulins)
interfering with the 2D-gel analysis, and to enrich the fH and CFHRs preparations. Isoform patterns corresponding to fH, CFHR4A, and CFHR5 were identified based upon their molecular weights. Isoform patterns corresponding to CFHR1, CFHL1, For personal use only. on August 16, 2017. by guest www.bloodjournal.org From CFHR3 and CFHR4B were assigned by comparison with the 2D-gels obtained from serum samples of aHUS patients with complete deficiencies of CFHR1 and/or CFHR3 (figure 4B). Differences between the theoretical and the observed isoelectric points were evident for most of the CFHR proteins ( figure 4A ), suggesting the existence of posttranslational modifications that attached charged residues to the carbohydrate molecules of these proteins.
To determine whether the isoform patterns of the CFHR proteins remained constant in different individuals, we analyzed 6 additional control individuals (samples C2 to C7) and a "pooled" sample including the 7 controls (sample P). All samples were analyzed using IPG strips of three pH ranges to optimize isoform resolution of the different CFHR proteins.
Good separation of CFHR3 and CFHR4B by two-dimensional electrophoresis was achieved by using IPG strips in the pH range 3-10 ( figure 5A ). Both proteins present a ladder pattern, but CFHR3 isoforms are more acidic, with an estimated pI Resolution of the CFHR1/CFHL1 region was improved by using IPG strips pH 5-8 in the isoelectrofocusing step, 10% SDS-PAGE in the second dimension, and Western-blot with a monoclonal antibody that recognizes CFHL1 but not CFHR1.
These conditions allowed proper identification of protein spots in the region, permitting discrimination between CFHL1 and CFHR1 isoforms. As shown in figure 6A , two CFHL1 isoforms differing in molecular weight and pI were detected in the control sample analyzed. The minor isoform, partially overlapping with one of the CFHR1β isoforms, cannot be easily appreciated using IPG strips in the pH range 3-10 ( figure   4A ). To confirm that the spots in the region assigned to CFHR1 isoforms indeed correspond to CFHR1, a replicate gel was stained with Coomassie Brilliant Blue G-250 and the spots matching those in the Western-blot shown in figure 6A were picked up (Table VIII) . These data unravel a novel risk factor for aHUS and suggest that normal expression of the CFHR1*B allotype, more similar to fH, may compete or interfere the normal function of fH, decreasing protection of cellular surfaces from damage by complement.
DISCUSSION
Complement factor H-related (CFHR) proteins are a group of minor plasma proteins that show structural and genetic homology to fH 7 . Evolution of this family has resulted in genomic duplications that extend along the CFH-CFHRs subregion of the RCA gene cluster 8 , and are the basis for the strong sequence similarity among fH and the CFHR proteins. The presence of these duplicated regions, however, favors gene conversion and non-homologous recombination events that have been associated to atypical Hemolytic Uremic Syndrome (aHUS) 3 .
We report here the use of one-dimensional and two-dimensional (2D) gel electrophoresis combined with Western-blot to analyze the CFHR proteins in plasma samples from aHUS and MPGN2/DDD patients. These analyses have resulted in the identification of individuals carrying three novel CFHR protein deficiencies, DefR1, DefR3 and DefR1R4A, and have revealed a previously unrecognized CFHR1 polymorphism. Genetic analysis in individuals carrying these novel variations demonstrated that they have in part been generated as a consequence of the genomic instability in this region of the RCA gene cluster.
As expected from previous studies, DefR1R3 is the most frequent deficiency of CFHR proteins in our control population and in the patient cohorts. In agreement with previous results 16 both the allelic frequency of Δ CFHR1-CFHR3 and the number of homozygotes are significantly associated with protection from AMD in the Spanish population (Table IV) . In aHUS patients, however, we could not replicate previous reports 17 indicating that the Δ CFHR1-CFHR3 allele is associated with increased predisposition to the disease; we found no differences between patients and controls for the frequency of the Δ CFHR1-CFHR3 allele. Importantly, our aHUS population is out of Hardy-Weinberg equilibrium for the CFHR1 polymorphism due to an excess of Δ CFHR1-CFHR3 homozygotes (pattern DefR1R3). Therefore, we conclude that the reported association of Δ CFHR1-CFHR3 with increased risk to aHUS only holds true for homozygous carriers.
A significant number of Δ CFHR1-CFHR3 homozygotes carry anti-fH autoantibodies 20 , but whether a deficiency of CFHR1/CFHR3 is pathologically relevant, or it is a marker for a different genetic defect, is currently unknown. An important finding in our studies is the recognition that two aHUS patients with anti-fH autoantibodies presented homozygous deficiency of CFHR1 but not of CFHR3 ( is homozygote for a novel genomic deletion involving the CFHR1 and CFHR4 genes (Δ CFHR1-CFHR4 ). Thus, among the 7 patients carrying anti-fH autoantibodies in our aHUS series, 5 of them presented deficiency of CFHR1 as a consequence of 3 different genetic alterations. These data highlight a direct relationship between the lack of CFHR1 and the presence of anti-fH autoantibodies. They also suggest that the association of the autoantibodies with the genomic deletion encompassing CFHR1 and CFHR3 (Δ CFHR1-CFHR3 ) is secondary to this relationship. This conclusion is further supported by the fact that only 3 of the 12 homozygous Δ CFHR1-CFHR3 aHUS patients develop anti-fH autoantibodies. In addition, the two patients with a single CFHR3 deficiency were negative for the anti-fH autoantibodies.
There is no clear explanation for the association between the deficiency of CFHR1 and the presence of anti-fH autoantibodies in aHUS patients. These autoantibodies have been reported to recognize SCRs19-20 of fH, 29 which are involved in binding to glycosaminoglycans and surface-bound C3b 30 . As illustrated in figure 7B , these SCRs are nearly identical to SCRs4-5 of CFHR1, so it is likely they can also recognize this protein. Unpublished data from our group suggest that anti-fH autoantibodies from CFHR1-deficient patients (patients H108, H154 and H177 in this report) cross-react with CFHR1, while this crossreactivity was not observed in the only patient with a normal CFHR1 expression that we could study (patient H151). Therefore, the autoantibodies in individuals expressing CFHR1 may be different to those present in CFHR1-deficient individuals. We would like to suggest that autoantibodies generated in the context of a CFHR1 deficiency are targeted to a region of the fH molecule that is critical for the developing of aHUS.
The physiological function of CFHR1 is beginning to be understood. A recent report 14 suggests CFHR1 has a complement regulatory activity at the level of the alternative pathway C5 convertase and the lytic pathway, a function mediated through the binding of the SCRs1-2 domains of CFHR1 to C5 and C5b6. Moreover, CFHR1 would also compete with fH for C3b and polyanionic binding on cell surfaces, thus interfering with the complement regulatory activity of fH. This potential fH-CFHR1 functional interference on cellular surfaces relies on the strong sequence similarity For personal use only. on August 16, 2017. by guest www.bloodjournal.org From between SCRs 18-20 of fH and SCRs 3-5 of CFHR1, and is supported by genetic data from aHUS patients 15, 24 .
Characterization of CFHR1 by two-dimensional gel electrophoresis and
Western-blot revealed acidic and basic isoforms of this protein in control individuals ( Figure 6 ). Genetic studies showed that the acidic and basic isoforms are indeed two CFHR1 allotypes (CFHR1*A and CFHR1*B) that differ in 3 amino acids within the SCR3 domain. Interestingly, these 3 amino acid differences make the SCR3 domain of the CFHR1*B allotype identical to the SCR18 domain of fH ( figure 7B ). The two CFHR1 allotypes most likely correspond to the two human liver cDNA clones previously described 31 , which generated by a gene conversion event between the CFHR1 and the CFH genes. We present here the results of a case-control association study in the aHUS Spanish cohort showing that CFHR1*B, the allele presenting the highest sequence similarity to CFH, is strongly associated with increased risk to aHUS when it is present in homozygosity (two copies) (Table VIII) . These are novel and interesting data that may reflect a competition between CFHR1 and fH, decreasing the functional activity of fH on surfaces and thus predisposing to complement-mediated damage.
In conclusion, the analysis of CFHR proteins using one or two-dimensional gel electrophoresis and Western-blot have allowed us to explore additional variability in the CFH-CFHR1-5 genomic region, providing new structural data on these proteins. For the first time, we have identified isolated deficiencies of CFHR1 and CFHR3, and established a specific relationship between the CFHR1 deficiency and the generation of anti-fH autoantibodies associated with aHUS. The discovery of a common CFHR1 allotype, which is associated with increased risk for aHUS, is an exciting finding that may unravel a functional interference between CFHR1 and fH with consequences in pathology. These novel data warrant new studies that, in addition to increasing our understanding of the CFHR proteins, will likely improve our knowledge of the pathogenic mechanisms in aHUS.
TABLES TABLE I. Probes for MLPA analysis of the CFH-CFHR1-5 region
Probe
Hybridizing sequence (5´to 3´) isoforms.The theoretical isoelectric points calculated with Compute pI/Mw program at ExPASy server (http://ca.expasy.org/tools/pi_tool.html) were: CFH (6.12); CFHL1 (6.77); CFHR1 (7.53); CFHR3 (7.79); CFHR4A (4.85); CFHR4B (5.16); CFHR5 (6.87). 
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